Compare ALEMBIC with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs SUN PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC SUN PHARMA ALEMBIC/
SUN PHARMA
 
P/E (TTM) x 61.0 78.4 77.7% View Chart
P/BV x 5.3 3.3 157.1% View Chart
Dividend Yield % 0.2 0.6 30.5%  

Financials

 ALEMBIC   SUN PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
SUN PHARMA
Mar-20
ALEMBIC/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs72484 14.9%   
Low Rs34315 10.8%   
Sales per share (Unadj.) Rs4.7136.9 3.4%  
Earnings per share (Unadj.) Rs6.117.5 35.0%  
Cash flow per share (Unadj.) Rs6.226.0 24.0%  
Dividends per share (Unadj.) Rs0.204.00 5.0%  
Dividend yield (eoy) %0.41.0 37.7%  
Book value per share (Unadj.) Rs40.7188.7 21.6%  
Shares outstanding (eoy) m267.032,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.9 385.8%   
Avg P/E ratio x8.722.9 37.9%  
P/CF ratio (eoy) x8.515.4 55.2%  
Price / Book Value ratio x1.32.1 61.5%  
Dividend payout %3.322.9 14.3%   
Avg Mkt Cap Rs m14,139958,864 1.5%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m20763,624 0.3%   
Avg. sales/employee Rs ThNM18,490.6-  
Avg. wages/employee Rs ThNM3,582.6-  
Avg. net profit/employee Rs ThNM2,357.6-  
INCOME DATA
Net Sales Rs m1,255328,375 0.4%  
Other income Rs m3706,360 5.8%   
Total revenues Rs m1,625334,735 0.5%   
Gross profit Rs m11169,898 0.2%  
Depreciation Rs m3820,528 0.2%   
Interest Rs m23,027 0.1%   
Profit before tax Rs m44252,702 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m248,228 0.3%   
Profit after tax Rs m1,63041,868 3.9%  
Gross profit margin %8.921.3 41.6%  
Effective tax rate %5.415.6 34.7%   
Net profit margin %129.812.8 1,018.4%  
BALANCE SHEET DATA
Current assets Rs m1,867316,542 0.6%   
Current liabilities Rs m591157,064 0.4%   
Net working cap to sales %101.648.6 209.3%  
Current ratio x3.22.0 156.7%  
Inventory Days Days9488 107.7%  
Debtors Days Days74105 70.2%  
Net fixed assets Rs m1,791243,102 0.7%   
Share capital Rs m5342,399 22.3%   
"Free" reserves Rs m10,324450,245 2.3%   
Net worth Rs m10,858452,645 2.4%   
Long term debt Rs m4120,289 0.2%   
Total assets Rs m11,591682,525 1.7%  
Interest coverage x260.918.4 1,417.1%   
Debt to equity ratio x00 8.5%  
Sales to assets ratio x0.10.5 22.5%   
Return on assets %14.16.6 214.0%  
Return on equity %15.09.2 162.3%  
Return on capital %15.211.2 135.2%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1974,219 0.0%   
Fx outflow Rs m26427,964 0.9%   
Net fx Rs m-24446,255 -0.5%   
CASH FLOW
From Operations Rs m23665,548 0.4%  
From Investments Rs m-224-25,888 0.9%  
From Financial Activity Rs m-27-57,151 0.0%  
Net Cashflow Rs m-15-13,857 0.1%  

Share Holding

Indian Promoters % 64.0 63.7 100.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.1 3.9%  
FIIs % 9.7 23.0 42.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 8.3 314.5%  
Shareholders   54,701 133,026 41.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tumbles 600 Points Tracking Global Selloff; HDFC & Tata Steel Top Losers(09:30 am)

A fresh spike in US bond yields and a firm dollar triggered a selloff in Asian share markets today.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Mar 4, 2021 12:10 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - IPCA LABS COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS